NYSEARCA:PBE Invesco Biotechnology & Genome ETF (PBE) Price, Holdings, & News $68.45 +0.25 (+0.37%) Closing price 08/29/2025 04:10 PM EasternExtended Trading$68.48 +0.03 (+0.05%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock About Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PBE alerts:Sign Up Key Stats Today's Range$68.06▼$68.4550-Day Range$63.38▼$68.8452-Week Range$54.52▼$72.84Volume2,052 shsAverage Volume8,391 shsMarket Capitalization$236.15 millionAssets Under Management$218.41 millionDividend Yield0.23%Net Expense Ratio0.58%Aggregate RatingModerate Buy ETF Overview PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser. Read More Invesco Biotechnology & Genome ETF ExpensesTypePBEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.50%0.56%0.56%0.51%0.53%Other Expenses0.08%0.47%0.56%0.59%0.56%Total Expense0.58%0.75%0.76%0.74%0.73%Fee Waiver0.00%-0.67%-0.66%-0.71%-0.63%Net Expense0.58%0.60%0.63%0.58%0.60% Receive PBE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invesco Biotechnology & Genome ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBE ETF News HeadlinesPBE Invesco Biotechnology & Genome ETFJanuary 29, 2025 | seekingalpha.comInvesco Dynamic Biotech & Genome ETF (PBE)August 31, 2024 | uk.finance.yahoo.comBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%.August 30 at 2:00 AM | Altimetry (Ad)Invesco Dynamic Biotechnology & Genome ETF declares quarterly distribution of $0.0242March 22, 2024 | msn.com3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough PotentialFebruary 19, 2024 | investorplace.comWhere Are Biotech ETFs Headed After Q4 Earnings?February 14, 2024 | msn.comSee More Headlines PBE ETF - Frequently Asked Questions How have PBE shares performed this year? Invesco Biotechnology & Genome ETF's stock was trading at $66.53 on January 1st, 2025. Since then, PBE stock has increased by 2.9% and is now trading at $68.45. Who are Invesco Biotechnology & Genome ETF's major shareholders? Top institutional shareholders of Invesco Biotechnology & Genome ETF include Gerber Kawasaki Wealth & Investment Management (7.37%), Bank of America Corp DE (1.69%), YHB Investment Advisors Inc. (0.70%) and Cetera Investment Advisers (0.59%). How do I buy shares of Invesco Biotechnology & Genome ETF? Shares of PBE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invesco Biotechnology & Genome ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invesco Biotechnology & Genome ETF investors own include Micron Technology (MU), Pfizer (PFE), Devon Energy (DVN), Intel (INTC), Activision Blizzard (ATVI), NVIDIA (NVDA) and Bristol Myers Squibb (BMY). Fund Details IssuerInvesco Fund NameInvesco Biotechnology & Genome ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:PBE Inception Date6/23/2005 Fund ManagerPeter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser Webwww.invescopowershares.com Phone+1-800-9830903Fund Focus Asset ClassEquity BenchmarkDynamic Biotech & Genome Intellidex Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings30 Fund Statistics Assets Under Management$217.55 million Average Daily Volume$16.67 thousand Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorInvesco Capital Management, LLC CustodianThe Bank of New York Mellon Corporation DistributorInvesco Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCitadel Options OptionableOptionable Options Volume1 Put Options5 Call Options1 Short Interest600 shs Miscellaneous Outstanding Shares3,450,000Beta0.87 Creation Unit10,000 Creation Fee$500.00 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Top 10 PBE HoldingsAlnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 7.46%Illumina (NASDAQ:ILMN)Holding Weight: 5.76%Royalty Pharma (NASDAQ:RPRX)Holding Weight: 5.63%BioMarin Pharmaceutical (NASDAQ:BMRN)Holding Weight: 5.09%Amgen (NASDAQ:AMGN)Holding Weight: 5.07%Gilead Sciences (NASDAQ:GILD)Holding Weight: 5.03%United Therapeutics (NASDAQ:UTHR)Holding Weight: 4.73%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 4.19%Anavex Life Sciences (NASDAQ:AVXL)Holding Weight: 4.13%Incyte (NASDAQ:INCY)Holding Weight: 3.25%Full Holdings DetailsPBE Sector ExposurePBE Industry Exposure This page (NYSEARCA:PBE) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredMy NEXT $1 Trillion PredictionJames Altucher is making his next trillion-dollar prediction — and this time, it’s not Apple. He believes Elon...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
